EDAP TMS SA annual report, Q4 FY2014

EDAP TMS S.A. — FY 2014 Form 20-F

Reporting period: Fiscal year ended December 31, 2014; filed April 2, 2015. This is an annual report, not a standalone fourth-quarter filing, and the provided text does not give a clear Q4-only financial breakdown. Financial statements are prepared under U.S. GAAP and reported in euros.

Business context

EDAP develops and sells minimally invasive urology devices through its HIFU division, focused on prostate treatment, and its Urology Devices and Services (UDS) division, principally focused on lithotripsy for urinary stones. UDS remains the larger business; the company identifies HIFU as an important potential source of future growth.

Key financial results

Metric (€ millions, except EPS)20142013Change / context
Total revenue26.824.1Up 11.2%
Net sales26.324.1Up 9.1%
Gross profit11.29.3Gross margin 42.7%, up from 38.7%
Operating loss1.72.8Loss narrowed
Net loss0.55.0EPS: (€0.02), versus (€0.24)
Cash used in operating activities1.02.5Still negative, but improved

The 2014 net loss was supported by €1.8 million of net financial income, including a €1.7 million non-cash gain from fair-value changes in warrants. Foreign-exchange losses were €0.4 million, versus €1.2 million in 2013. The operating loss therefore remains an important indicator alongside net income.

Divisions: HIFU net sales rose to €8.2 million from €5.1 million; the division reported operating income of €1.2 million, versus a €0.7 million loss. EDAP sold four Ablatherm and six Focal One units, compared with three HIFU units in 2013. UDS net sales declined to €18.1 million from €19.0 million; device sales fell to 42 units from 45, while parts, services, leasing and procedure revenues increased. UDS reported an operating loss of €0.2 million, versus €0.5 million operating income.

Cash, liquidity and debt

  • Cash and cash equivalents at year-end were €11.1 million; short-term investments were €1.0 million, bringing the reported combined cash and investment position to €12.1 million. The €1.0 million investment was pledged as collateral for a €1.0 million short-term loan.
  • Cash increased €4.5 million during 2014, principally because of €6.2 million net proceeds from the June 2014 share placement. Operating cash use was €1.0 million and investing cash use was €1.0 million.
  • Year-end short-term borrowings were €2.1 million; long-term debt was €0.5 million in total, including €0.1 million current. Capital lease obligations were €0.6 million. Separately, the balance sheet included €2.1 million of warrant liabilities, which are fair-value instruments rather than conventional borrowings.
  • Current assets were €26.6 million and current liabilities €12.2 million. Management stated that working capital was sufficient for then-current requirements, while warning that regulatory delays, commercialization spending or weaker collections could require additional capital.

Changes, outlook and material risks

  • Revenue growth was led by HIFU device sales, while UDS device sales and total division revenue declined. Gross margin improved, but consolidated operations remained loss-making.
  • FDA advisers voted negatively in July 2014 on Ablatherm’s safety, efficacy and risk-benefit profile for low-risk localized prostate cancer. In November, the FDA said the PMA was not approvable in its current form. After further discussions, EDAP announced in March 2015 that it planned to pursue a de novo 510(k) pathway for a prostate-tissue-ablation claim. The submission requirements and timing remained uncertain; U.S. commercial clearance had not been obtained.
  • Management expected European R&D spending, excluding U.S. FDA clearance costs, to remain around 10% of revenue from 2015. It expected continued significant sales and marketing spending. No specific revenue or earnings guidance was provided.
  • Management cited continuing operating losses, negative operating cash flow, dependence on HIFU adoption and reimbursement, FDA and other regulatory uncertainty, seasonal and order-driven revenue variability, intense competition in mature lithotripsy markets, foreign-exchange exposure, reliance on a single manufacturing site and certain single-source suppliers.
  • A U.S. securities class action relating to alleged statements about Ablatherm and FDA interactions was pending. EDAP accrued $206,000 for legal costs and recorded no additional loss contingency; it said the outcome could not be predicted. The company also continued an appeal concerning a French tax-authority recovery request relating to historic state aid; the filing describes €773,000 as having been requested and paid, with the recovery dispute ongoing.
  • Post-year-end developments disclosed in the filing included Canadian approval of Focal One, a urological-laser OEM partnership, a €2.4 million Bpifrance contribution over five years for liver-cancer development, and additional shares issued following warrant exercises.

Most important facts for investors to verify

  • Progress, required evidence, timing and potential scope of the Ablatherm de novo 510(k) submission and any subsequent FDA decision.
  • Whether HIFU sales growth and reported HIFU operating profit can continue, and whether UDS can recover as equipment sales weaken.
  • Cash availability after accounting for the pledged €1.0 million investment, ongoing operating cash use, capital needs and warrant-related dilution.
  • The source and sustainability of the 2014 net-income improvement, particularly the non-cash warrant fair-value gain.
  • Developments in the securities litigation and French tax appeal, and any resulting costs or liabilities.
  • Reimbursement, physician adoption and commercial performance in markets where HIFU products are approved.

The independent auditor issued an unqualified opinion on the consolidated financial statements and concluded that internal control over financial reporting was effective as of December 31, 2014.

Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.